Avanir Agrees to $116 Million Settlement for Alleged Kickbacks

Drug Industry Daily
A A
Otsuka subsidiary Avanir Pharmaceuticals agreed to pay approximately $116 million to settle whistleblower fraud allegations that the company offered kickbacks to doctors and salespeople to push Nuedexta off label for dementia patients.

To View This Article:

Login

Subscribe To Drug Industry Daily